InnoCare Pharma (FRA:33C) EBIT per Share : €-0.03 (TTM As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is InnoCare Pharma EBIT per Share?

InnoCare Pharma's EBIT per Share for the three months ended in Dec. 2023 was €-0.01. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 was €-0.03.

During the past 3 years, the average EBIT per Share Growth Rate was 11.40% per year. During the past 5 years, the average EBIT per Share Growth Rate was -22.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for InnoCare Pharma's EBIT per Share or its related term are showing as below:

FRA:33C' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -112.7 Med: -19.3 Max: 11.4
Current: 11.4

During the past 7 years, the highest 3-Year average EBIT per Share Growth Rate of InnoCare Pharma was 11.40% per year. The lowest was -112.70% per year. And the median was -19.30% per year.

FRA:33C's 3-Year EBIT Growth Rate is ranked better than
60.03% of 1311 companies
in the Biotechnology industry
Industry Median: 3.6 vs FRA:33C: 11.40

InnoCare Pharma's EBIT for the three months ended in Dec. 2023 was €-13.59 Mil.

InnoCare Pharma EBIT per Share Historical Data

The historical data trend for InnoCare Pharma's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InnoCare Pharma EBIT per Share Chart

InnoCare Pharma Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

Get a 7-Day Free Trial

-0.22

-0.05

-0.08

-0.05

InnoCare Pharma Quarterly Data
	Dec17	Sep18	Dec18	Jun19	Sep19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Sep22	Dec22	Jun23	Sep23	Dec23	Mar24
EBIT per Share	Get a 7-Day Free Trial												-0.03	-	-0.01	-0.01	-0.01

InnoCare Pharma EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

InnoCare Pharma's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-78.235	/	1687.470
=	-0.05

InnoCare Pharma's EBIT per Share for the quarter that ended in Dec. 2023 is calculated as

	EBIT per Share		(Q: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-13.586	/	1609.569
=	-0.01

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.03

InnoCare Pharma (FRA:33C) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

InnoCare Pharma EBIT per Share Related Terms

Thank you for viewing the detailed overview of InnoCare Pharma's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

InnoCare Pharma (FRA:33C) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InnoCare Pharma Ltd (FRA:33C) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

09969:Hong Kong 33C:Germany 688428:China

Address

No. 8 Life Science Park Road, Building 8, Zhongguancun Life Science Park, Changping District, Beijing, CHN, 102206

Website

https://www.innocarepharma.com

InnoCare Pharma Ltd is a commercial-stage biopharmaceutical company. It discovers, develops, and commercializes drugs for the treatment of cancer and autoimmune diseases. The company's main product pipeline includes orelabrutinib, ibrutinib, zanubrutinib, tafasitamab, ICP-490, ICP-B02, ICP-248, ICP-192, ICP-723, and ICP-189, among others. Its products are mainly used to treat hematological tumors, solid tumors, and autoimmune diseases. The company is also developing products for the treatment of autoimmune diseases caused by abnormal B-cell or T-cell function.

InnoCare Pharma (FRA:33C) Headlines

No Headlines